Tevogen Bio Holdings Inc. (TVGN)

NGM – Real vaqt narxi. Valyuta: USD

6.97

-0.11 (-1.55%)

Yopilishda: May 12, 2026, 4:00 PM EDT

12.05.2026

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close

WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it has entered into a securities purchase agreement for a private investment in public equity (the “PIPE”) financing with existing investor The Patel Family, LLP for gross proceeds of $3 million.

27.04.2026

Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal

WARREN, N.J., April 27, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced continued progress within its artificial intelligence initiative, Tevogen.AI, including the near completion of its PredicTcell™ training algorithm and early steps toward commercial readiness.

26.03.2026

Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth

Potential transaction expected to add $20M+ in revenue and support double-digit growth, further strengthening Tevogen's position in oncology, rare diseases, and medical devices Target CRO operates across 20+ countries, providing global clinical development capabilities WARREN, N.J., March 26, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it is in advanced-stage evaluation of a niche contract research organization (CRO) with multi-country operations and established relationships across oncology, rare diseases, and medical devices.

25.03.2026

Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement

WARREN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) received written notice (the “Notification Letter”) from The Nasdaq Stock Market LLC notifying the Company that it had regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) for continued listing on The Nasdaq Global Market.

18.03.2026

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)

WARREN, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, will speak at the Microsoft Fabric Community Conference (FabCon 2026), taking place March 16–20, 2026, in Atlanta, Georgia.

13.03.2026

Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization

Tevogen highlights capital discipline, minimal share use, strong insider ownership, and potential acquisitions while exploring ways to reflect asset value

13.03.2026

Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure

WARREN, N.J., March 13, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced performance advancements for its artificial intelligence platform, operated through Tevogen.AI.

Videolar

No Data

There is no data to display

Press-relizlar

12.05.2026

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close

27.04.2026

Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal

26.03.2026

Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth

25.03.2026

Tevogen Bio Holdings Inc. (TVGN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Tevogen Bio Holdings Inc. (TVGN)

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close

Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal

Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth

Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)

Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization

Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure

Videolar

No Data

Press-relizlar

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close

Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal

Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth

Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close

Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal

Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth

Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)

Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization

Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure

Videolar

No Data

Press-relizlar

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close

Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal

Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth

Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement

Search stocks

Tevogen Bio Holdings Inc. (TVGN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Tevogen Bio Holdings Inc. (TVGN)

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close

Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal

Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth

Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)

Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization

Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure

Videolar

No Data

Press-relizlar

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close

Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal

Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth

Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close

Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal

Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth

Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)

Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization

Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure

Videolar

No Data

Press-relizlar

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close

Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal

Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth

Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement